Fiera Capital Corp Acquires 380,027 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Fiera Capital Corp raised its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 41.4% in the second quarter, Holdings Channel reports. The fund owned 1,297,302 shares of the company’s stock after purchasing an additional 380,027 shares during the quarter. Fiera Capital Corp’s holdings in SpringWorks Therapeutics were worth $48,869,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. First Horizon Advisors Inc. grew its position in SpringWorks Therapeutics by 47.9% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock worth $45,000 after acquiring an additional 383 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of SpringWorks Therapeutics in the second quarter worth $123,000. CANADA LIFE ASSURANCE Co increased its holdings in SpringWorks Therapeutics by 20.3% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,465 shares of the company’s stock valued at $220,000 after purchasing an additional 754 shares during the period. SG Americas Securities LLC raised its position in SpringWorks Therapeutics by 8.3% during the 1st quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock worth $230,000 after purchasing an additional 358 shares during the last quarter. Finally, Financial Security Advisor Inc. acquired a new position in SpringWorks Therapeutics during the 1st quarter worth about $246,000.

SpringWorks Therapeutics Stock Up 1.9 %

Shares of SWTX opened at $41.71 on Tuesday. The firm’s fifty day simple moving average is $37.94 and its two-hundred day simple moving average is $42.48. SpringWorks Therapeutics, Inc. has a 12 month low of $18.00 and a 12 month high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.58. The company had revenue of $59.73 million for the quarter, compared to analyst estimates of $34.42 million. The firm’s revenue was up 59732900.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.25) EPS. On average, equities research analysts predict that SpringWorks Therapeutics, Inc. will post -3.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and issued a $77.00 price target (up previously from $75.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, August 28th. HC Wainwright reissued a “buy” rating and set a $76.00 target price on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics has an average rating of “Buy” and a consensus target price of $69.50.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.